KR102119985B1 - ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법 - Google Patents

ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법 Download PDF

Info

Publication number
KR102119985B1
KR102119985B1 KR1020187006399A KR20187006399A KR102119985B1 KR 102119985 B1 KR102119985 B1 KR 102119985B1 KR 1020187006399 A KR1020187006399 A KR 1020187006399A KR 20187006399 A KR20187006399 A KR 20187006399A KR 102119985 B1 KR102119985 B1 KR 102119985B1
Authority
KR
South Korea
Prior art keywords
cells
mrna
cell
protein
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187006399A
Other languages
English (en)
Korean (ko)
Other versions
KR20180026811A (ko
Inventor
마크 씨 허즈버그
카렌 파니 로스
브렌트 에스 소렌슨
Original Assignee
마크 씨 허즈버그
카렌 파니 로스
브렌트 에스 소렌슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크 씨 허즈버그, 카렌 파니 로스, 브렌트 에스 소렌슨 filed Critical 마크 씨 허즈버그
Publication of KR20180026811A publication Critical patent/KR20180026811A/ko
Application granted granted Critical
Publication of KR102119985B1 publication Critical patent/KR102119985B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187006399A 2013-01-11 2014-01-10 ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법 Active KR102119985B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
US61/751,504 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157021685A Division KR102056511B1 (ko) 2013-01-11 2014-01-10 ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20180026811A KR20180026811A (ko) 2018-03-13
KR102119985B1 true KR102119985B1 (ko) 2020-06-05

Family

ID=51167392

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187006399A Active KR102119985B1 (ko) 2013-01-11 2014-01-10 ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법
KR1020157021685A Active KR102056511B1 (ko) 2013-01-11 2014-01-10 ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157021685A Active KR102056511B1 (ko) 2013-01-11 2014-01-10 ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법

Country Status (13)

Country Link
US (3) US20150344537A1 (https=)
EP (2) EP2943226B1 (https=)
JP (4) JP2016511230A (https=)
KR (2) KR102119985B1 (https=)
CN (1) CN105473163A (https=)
AU (1) AU2014205298B2 (https=)
CA (2) CA2901409C (https=)
ES (1) ES2738315T3 (https=)
IL (2) IL239898B (https=)
NZ (1) NZ710495A (https=)
PL (1) PL2943226T3 (https=)
SG (2) SG11201505431XA (https=)
WO (1) WO2014110366A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344537A1 (en) * 2013-01-11 2015-12-03 Mark C. Herzberg Non-Transgene Transfection for Therapeutic Purposes
US11253570B2 (en) 2016-11-07 2022-02-22 Medizinische Hochschule Hannover (Mhh) S100A8/S100A9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
WO2001023002A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
WO2002022686A2 (en) * 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US20070123455A1 (en) * 2003-04-04 2007-05-31 Joel Palefsky Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US8679811B2 (en) * 2007-06-11 2014-03-25 The University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
EP2691101A2 (en) * 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
US20150344537A1 (en) * 2013-01-11 2015-12-03 Mark C. Herzberg Non-Transgene Transfection for Therapeutic Purposes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Khammanivong, Ali., University of Minnesota. (2011.07. 공개)*
Thierry Bettinger et al., Nucleic acids research, Vol. 29(18), pages 3882-3891 (2001년 공개)*

Also Published As

Publication number Publication date
JP2016511230A (ja) 2016-04-14
AU2014205298A1 (en) 2015-08-13
SG10201603946PA (en) 2016-07-28
US20200231640A1 (en) 2020-07-23
KR102056511B1 (ko) 2019-12-16
EP2943226B1 (en) 2019-03-13
IL239898A0 (en) 2015-08-31
US11912744B2 (en) 2024-02-27
IL239898B (en) 2018-10-31
JP2019031521A (ja) 2019-02-28
JP2021019644A (ja) 2021-02-18
KR20160031999A (ko) 2016-03-23
CA2901409C (en) 2022-06-07
WO2014110366A1 (en) 2014-07-17
IL262252B (en) 2020-06-30
ES2738315T3 (es) 2020-01-21
AU2014205298B2 (en) 2018-11-01
EP2943226A1 (en) 2015-11-18
JP6956059B2 (ja) 2021-10-27
US20150344537A1 (en) 2015-12-03
CN105473163A (zh) 2016-04-06
EP3501551A1 (en) 2019-06-26
KR20180026811A (ko) 2018-03-13
SG11201505431XA (en) 2015-08-28
NZ710495A (en) 2019-10-25
US20240166701A1 (en) 2024-05-23
PL2943226T3 (pl) 2019-09-30
EP3501551C0 (en) 2023-06-07
IL262252A (en) 2018-11-29
CA3152721A1 (en) 2014-07-17
CA2901409A1 (en) 2014-07-17
US12448421B2 (en) 2025-10-21
JP6473729B2 (ja) 2019-02-20
EP2943226A4 (en) 2016-11-23
EP3501551B1 (en) 2023-06-07
JP2017052781A (ja) 2017-03-16
CA3152721C (en) 2025-11-18

Similar Documents

Publication Publication Date Title
US12448421B2 (en) Non-transgene transfection for therapeutic purposes
CN102459571B (zh) 抗炎细菌
Liu et al. β‐Arrestin1‐mediated decrease in endoplasmic reticulum stress impairs intestinal stem cell proliferation following radiation
Kang et al. Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells
CN114606323B (zh) 一种识别胃癌干细胞的标志物lgsn作为胃癌诊断和治疗靶标的应用
KR101501799B1 (ko) 세포의 자가소화작용 유도용 조성물
WO2024230090A1 (zh) 唾液酸转移酶抑制剂在制备中和酸性肿瘤微环境的药物中应用
CN109069644B (zh) 用于预防或治疗癌症的方法和组合物
US20230270881A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
Alsanani et al. Stromal carcinoma associated fibroblasts promote drug resistance of human pancreatic cancer cells by modulation of ROS via CXCR4/CXCL12 signaling
US20250154215A1 (en) Pharmaceutical composition for treating colitis or colorectal cancer comprising colon-targeted s100a8/a9-derived specific peptide
Cook Targeting BCL-2 Family Proteins In Therapy Induced Senescent Cancer Cell Models
US9885044B2 (en) Polynucleotides and methods for inhibiting cancer cells
WO2025166631A1 (zh) Tmed10作为靶点在治疗炎症中的应用
JP2016023182A (ja) がんを処置するための医薬
홍지은 MyD88-dependent protective mechanism of alveolar macrophages induced by Bacillus subtilis spore in mice infected with respiratory syncytial virus A2
JP2012012330A (ja) 癌転移抑制剤及び医薬組成物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180305

Application number text: 1020157021685

Filing date: 20150811

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190108

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190307

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20191015

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200406

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200601

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200601

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240521

Start annual number: 5

End annual number: 5